The Biden administration and Pharmaceutical Care Management Association (PCMA), the trade association for pharmaceutical benefit managers (PBMs), have agreed to postpone, from January 1, 2022, to January 1, 2023, the effective date of the Trump administration rule eliminating safe harbor protection for manufacturer rebates to PBMs under Medicare Part D.
PCMA sued the U.S. Health and Human Services Department (HHS) on Jan. 26 to vacate the rebate rule’s effective date, saying the Trump administration issued the rule in violation of the Administrative Procedure Act. The Biden administration and PCMA agreed to the year-long postponement to give a federal district judge “the necessary time to review the entire rebate rule’s impact on Medicare Part D and its enrollees,” PCMA said.
The Biden administration and Pharmaceutical Care Management Association (PCMA), the trade association for pharmaceutical benefit managers (PBMs), have agreed to postpone, from January 1, 2022, to January 1, 2023, the effective date of the Trump administration rule eliminating safe harbor protection for manufacturer rebates to PBMs under Medicare Part D.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
